Morgan Stanley Global Healthcare Conference Update: Lilly, Amgen and Biogen
Pfizer and Merck KGaA are one step closer to a brand-new market for their immuno-oncology drug Bavencio. The companies reported winning data in a kidney cancer trial, setting them up … Continue Reading Can Pfizer and Merck KGaA parlay Bavencio combo data into a kidney cancer win?
It’s that time of the year, when drugmakers head to the European Society of Cardiology annual conference—the most influential scientific event for cardiovascular medicine on the Continent—in hopes that new … Continue Reading ESC need-to-know: Xarelto flops, Pfizer’s tafamidis wins, Entresto’s early use and more
Εγκρίθηκε στην Ε.Ε. η πρώτη νέα θεραπεία εδώ και 10 χρόνια για ασθενείς με ηπατοκυτταρικό καρκίνωμα. Πρόκειται για το φάρμακο Lenvima (λενβατινίμπη), που έχει αναπτυχθεί από τις εταιρείες Eisai και MSD. H έγκριση βασίστηκε σε … Continue Reading Νέα θεραπεία για ηπατοκυτταρικό καρκίνωμα
Bayer and Haplogen collaborate to develop new treatments against pulmonary diseases August 14, 2018 Bayer and Haplogen GmbH, a Vienna-based biotechnology company, have entered into a multi-year research collaboration agreement … Continue Reading Top Pharma News of the Week
It’s a busy week on the U.S. Food and Drug Administration (FDA)’s calendar, although the agency got ahead of itself and approved three of the applications early. Here’s a look. Agios Pharmaceuticals had … Continue Reading FDA Action Alert: Mallinckrodt, Kala Pharma, Merck, Eisai and More
The last two weeks have marked the second-quarterly financial report by numerous biopharma companies. Here’s a quick look at some of the major ones. On July 24, Biogen reported strong sales for the … Continue Reading A Roundup of Major Q2 Reports: Biogen, AstraZeneca, Pfizer and More
Bristol-Myers Squibb and Tsinghua University Announce Collaboration to Accelerate Early Research into Potential Therapies for Autoimmune Diseases and Cancer Bristol-Myers Squibb Company and Tsinghua University have entered into a collaboration to discover … Continue Reading Top Pharma News of the Week
Many analysts and investors were holding their breaths, waiting to see what Biogen would say at yesterday’s second-quarter financial report. The financials weren’t the focus, however, but what the Cambridge, Massachusetts biotech … Continue Reading Biogen’s Q2 Report Gets Investors Excited Again
Eisai Co. Ltd./Arena Pharmaceuticals Inc.‘s obesity drug Belviq (lorcaserin HCI) has proven that it doesn’t pose cardiovascular risks in the CAMELLIA-TIMI 61 cardiovascular outcomes study, but it hasn’t shown a benefit … Continue Reading Eisai’s Obesity Drug Belviq Passes Cardiovascular Outcomes Test
More than six years after winning approval, obesity drug Belviq has shown it’s heart-safe. But whether that claim can jump-start sales in an ice-cold market remains to be seen. … Continue Reading Eisai obesity drug Belviq may have an edge with new heart-safety data—but to what end?
Biogen and Japanese drugmaker Eisai created a surge in hope for an experimental Alzheimer’s drug called BAN2401, after the companies announced positive results in a late-stage trial. That … Continue Reading Did the market overreact to Biogen’s Alzheimer’s data?
Vertex Pharmaceuticals (VRTX) is the exception to worries for biotech companies heading into the second-quarter earnings season, an analyst said Friday. Historically, the second quarter represents a rebound for … Continue Reading Why Biopharma Is Bracing For Drug-Pricing Woes In Second Quarter
Biogen and Eisai announced positive topline results from their Phase II clinical trial of BAN2401 in Alzheimer’s disease. Before everyone gets too excited, it should be noted that the drug failed its primary goal at … Continue Reading Biogen Shares Positive Results in Alzheimer’s Phase II Trial
Looking ahead to 2018, the most promising products in pharma’s pipeline will compete in a landscape that increasingly rewards big risks and places an emphasis on novel mechanisms. That comes with … Continue Reading The 2018 pipeline report: Aspiring assets to keep an eye on